ANDA Filers Lose Again On Eliquis Patents With Monopoly Set For 2028
HEC’s Sunshine Lake Pharma, Sigmapharm and Unichem Fail On Appeal
ANDA filers that went to trial over Bristol Myers Squibb and Pfizer’s Eliquis blockbuster face a seven-year wait to launch their generic products after the US Court of Appeals for the Federal Circuit upheld a lower court decision.
You may also be interested in...
Generics Bulletin looks back at a selection of the most significant legal stories from 2022, including a major victory in the UK on the Eliquis blood thinner giant and continued action on generic label carve outs, which has the potential to reverberate through the US industry.
Apotex has introduced Canada’s first generic version of Eliquis in the form of its Apo-Apixaban product. The launch comes after the firm was also among a wave of Aubagio teriflunomide generics to hit the Canadian market.
Teva has capitalized on a recent legal victory in the UK by claiming the first launch of a generic apixaban rival to BMS’ Eliquis.